Innovation Days
About
Research
Products
Investors
Careers
Agenda
fr
Press Releases
Our latest news and press releases
All
2022
2021
2020
2019
2018
2017
04
Jan
2022
14:37 E.S.T.
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation
Read more
11
Dec
2021
10:11 E.S.T.
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
Read more
18
Nov
2021
13:44 E.S.T.
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China
Read more
11
Nov
2021
17:19 E.S.T.
Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer
Read more
04
Nov
2021
14:51 E.S.T.
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021
Read more
03
Nov
2021
18:40 E.S.T.
Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01
Read more
28
Oct
2021
11:08 E.S.T.
Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT
Read more
19
Oct
2021
14:19 E.S.T.
Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021
Read more
12
Oct
2021
14:53 E.S.T.
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Read more
26
Aug
2021
14:38 E.S.T.
Cellectis Announces Participation in Five Investor Conferences
Read more
Prev
1
2
3
4
5
Next